Chunyan Wang1, Shi Jin2, Shanqi Xu3, Shoubo Cao4. 1. Department of Medical and Radiation Oncology, Linyi People's Hospital, 27 Jie Fang Road, Linyi, 276003, Shandong, China. 2. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. 3. Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China. 4. Department of Medical and Radiation Oncology, Linyi People's Hospital, 27 Jie Fang Road, Linyi, 276003, Shandong, China. cs.bo@163.com.
Abstract
PURPOSE: Systemic immune-inflammation index (SII) has been demonstrated to be closely associated with prognosis of a series of solid tumors. However, its role in small cell lung cancer (SCLC) remains poorly understood. The present study aims to evaluate the prognostic significance of pretreatment SII in SCLC treated with etoposide and platinum-based chemotherapy. METHODS: Sixty hundred and fifty-three newly diagnosed SCLC patients were enrolled. The optimal cut-off values for SII and LDH (lactate dehydrogenase) were obtained by a receiver operating characteristic (ROC) curve analysis. Overall survival (OS) was assessed by univariate and multivariate analyses. RESULTS: The optimal cut-off values of pretreatment SII and LDH were 748.51 × 109/L and 188.5 U/L, respectively. High pretreatment SII was significantly associated with advanced tumor stage (limited disease, LD vs. extensive disease, ED; 26.3% vs 46.5%; p < 0.001). On univariate analysis, age < 65 years, female, non-smoker, limited disease, SII < 748.51 × 109/L, LDH < 188.5 U/L, distant metastasis numbers < 2, chemotherapy + radiotherapy, and chemotherapy + surgery were closely correlated with a prolonged OS (p < 0.05). The median OS for patients in high SII group was 12.0 months, compared with that of 17.0 months for patients in low SII group. Multivariate analysis showed smoking history (p = 0.014), tumor stage (p < 0.001), pretreatment SII (p < 0.001), LDH (p = 0.002), distant metastasis numbers (p = 0.006), and chemotherapy + radiotherapy (p < 0.001) were independent prognostic factors of OS. Furthermore, SII remained prognostic significance for SCLC stratified by variable subgroups analysis. CONCLUSION: Pretreatment SII represents a powerful prognostic biomarker for SCLC patients treated with etoposide and platinum-based chemotherapy. It is significant for treatment strategy making in clinics.
PURPOSE: Systemic immune-inflammation index (SII) has been demonstrated to be closely associated with prognosis of a series of solid tumors. However, its role in small cell lung cancer (SCLC) remains poorly understood. The present study aims to evaluate the prognostic significance of pretreatment SII in SCLC treated with etoposide and platinum-based chemotherapy. METHODS: Sixty hundred and fifty-three newly diagnosed SCLCpatients were enrolled. The optimal cut-off values for SII and LDH (lactate dehydrogenase) were obtained by a receiver operating characteristic (ROC) curve analysis. Overall survival (OS) was assessed by univariate and multivariate analyses. RESULTS: The optimal cut-off values of pretreatment SII and LDH were 748.51 × 109/L and 188.5 U/L, respectively. High pretreatment SII was significantly associated with advanced tumor stage (limited disease, LD vs. extensive disease, ED; 26.3% vs 46.5%; p < 0.001). On univariate analysis, age < 65 years, female, non-smoker, limited disease, SII < 748.51 × 109/L, LDH < 188.5 U/L, distant metastasis numbers < 2, chemotherapy + radiotherapy, and chemotherapy + surgery were closely correlated with a prolonged OS (p < 0.05). The median OS for patients in high SII group was 12.0 months, compared with that of 17.0 months for patients in low SII group. Multivariate analysis showed smoking history (p = 0.014), tumor stage (p < 0.001), pretreatment SII (p < 0.001), LDH (p = 0.002), distant metastasis numbers (p = 0.006), and chemotherapy + radiotherapy (p < 0.001) were independent prognostic factors of OS. Furthermore, SII remained prognostic significance for SCLC stratified by variable subgroups analysis. CONCLUSION: Pretreatment SII represents a powerful prognostic biomarker for SCLCpatients treated with etoposide and platinum-based chemotherapy. It is significant for treatment strategy making in clinics.
Entities:
Keywords:
Prognosis; Small cell lung cancer; Subgroup analysis; Systemic immune-inflammation index
Authors: Zachary D Horne; Robert Jack; Zachary T Gray; Jill M Siegfried; David O Wilson; Samuel A Yousem; Katie S Nason; Rodney J Landreneau; James D Luketich; Matthew J Schuchert Journal: J Surg Res Date: 2011-04-22 Impact factor: 2.192
Authors: Madhusmita Behera; Camille Ragin; Sungjin Kim; Rathi N Pillai; Zhengjia Chen; Conor E Steuer; Nabil F Saba; Chandra P Belani; Fadlo R Khuri; Suresh S Ramalingam; Taofeek K Owonikoko Journal: Cancer Date: 2015-10-06 Impact factor: 6.860
Authors: Mengliu Zhu; Li Chen; Xiangyi Kong; Xiangyu Wang; Xingrui Li; Yi Fang; Jing Wang Journal: Cancer Manag Res Date: 2022-02-25 Impact factor: 3.989